00882 TIANJIN DEV
- 1.970
- 0.0000.00%
TIANJIN DEV News
Featured announcements | Shunyu Optics' automotive lens shipments in April increased 15% year on year; sales of Yuexiu Real Estate fell nearly 50% year on year
Longyuan Electric Power: A total of 278.12,300 megawatt-hours of power generation was completed in the first 4 months, an increase of 2.59%; CGN New Energy completed a cumulative total of 6544.3 gigawatt-hours in the first 4 months, a decrease of 3.6% over the previous year.
Tianjin Development (00882.HK) subsidiary plans to sell 24.65% of Tianjin Tanabe Pharmaceutical's shares
Gelonghui, May 10 | Tianjin Development (00882.HK) announced that Lisheng Pharmaceutical (an indirect non-wholly-owned subsidiary of the company) plans to sell all 24.65% of its shares in Tianjin Tianbian through a public listing and sale process. The minimum listing price for the potential sale is RMB 120 million. Tianjin Tanabe is a limited company established in China. It is mainly engaged in the production, processing and sale of Chinese and Western medicines, chemicals, APIs, reagents, biopharmaceuticals and related services, as well as providing pharmaceutical information consultation. The potential sale is in line with Lisheng Pharmaceuticals' overall strategic plan. The Board believes that potential sales matters (if implemented) will improve
Tianjin Development Posts 77% Profit Jump for 2023
Tianjin Development Holdings' (HKG:0882) attributable profit surged to nearly HK$635.6 million for the year ended December 2023, as compared to HK$358.2 million in the previous year, according to a Th
Tianjin Development (00882.HK): Lisheng Pharmaceuticals' net profit of 59,155,600 yuan in the first quarter increased 27.22% year-on-year
Gelonghui, April 25 | Tianjin Development (00882.HK) announced that in the first quarter of 2024, Lisheng Pharmaceutical (002393.SZ) achieved operating income of 365 million yuan, up 8.71% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceutical) was 59,1556 million yuan, up 27.22% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceuticals) after deducting non-recurring profit and loss was 58.7736 million yuan, up 29.71% year on year; basic earnings per share were 0.32 yuan.
天津發展：天津力生製藥股份有限公司截至二零二四年三月三十一日止三個月之未經審核財務業績
天津發展：二零二三年年報
TIANJIN DEV To Go Ex-Dividend On June 20th, 2024 With 0.088 HKD Dividend Per Share
March 28th - $TIANJIN DEV(00882.HK)$ is trading ex-dividend on June 20th, 2024. Shareholders of record on June 21st, 2024 will receive 0.088 HKD dividend per share on July 29th, 2024. The ex-divid
Tianjin Development (00882): Central Pharmaceutical, a wholly-owned subsidiary of Lisheng Pharmaceuticals, received a civil ruling
Tianjin Development (00882) issued an announcement. Recently, Tianjin Lisheng Pharmaceutical Co., Ltd., a non-wholly-owned subsidiary of the company...
Tianjin Development's Chairman Steps Down; Successor Named
Wang Gang has resigned as chairman and executive director of Tianjin Development Holdings (HKG:0882), among other roles effective Wednesday, a same-day filing on the Hong Kong bourse said. On the same
Profit attributable to owners of Tianjin Development (00882.HK) in 2023 HK$636 million, final interest of HK8.8 cents
Gelonghui, March 27丨Tianjin Development (00882.HK) announced that in 2023, the company's revenue was HK$3.34 billion, compared to HK$3.705 billion in the same period last year; profit attributable to the company's owners was HK$636 million and profit of HK$358 million for the same period last year; it plans to distribute a final dividend of HK8.8 cents per share.
Tianjin Development (00882) will pay a final dividend of HK$0.088 per share on July 29
According to the Zhitong Finance App, Tianjin Development (00882) announced that it will pay a final dividend of HK$0.088 per share for the year ended December 31, 2023 on July 29, 2024.
TIANJIN DEV: Annoucement of Final Results for the year ended 31 December 2023
Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains From Asset Disposals; Shares Jump 4%
Tianjin Lisheng Pharmaceutical's (SHE:002393) attributable profit surged to 361.8 million yuan, or 1.97 yuan per share, in 2023, from 93.6 million yuan, or 0.51 yuan per share, in 2022, according to a
Tianjin Development (00882.HK): Lisheng Pharmaceuticals' net profit increased by 286.54% to 362 million yuan in 2023
Gelonghui, March 22丨Tianjin Development (00882.HK) announced that in 2023, Lisheng Pharmaceutical (002393.SZ) achieved operating income of RMB 1.153 billion, up 0.56% year on year; net profit attributable to shareholders of listed companies was 362 million yuan, up 286.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149.6 million yuan, up 20.26% year on year; basic earnings per share were 1.97 yuan.
TIANJIN DEV: Audited Financial Results for the year ended 31 December 2023 of Tianjin Lisheng Pharmaceutical Co., Ltd.
Tianjin Development (00882.HK) held a board meeting on March 27 to approve the release of annual results
Glonghui March 15 | Tianjin Development (00882.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to approve (among other things) the announcement of the annual results of the company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any).
TIANJIN DEV: Date of Board Meeting
Changes in Hong Kong stocks | Tianjin Development (00882) rose nearly 5% in the intraday period and is expected to increase net profit by about 70% to 80% year-on-year last year
Tianjin Development (00882) rose nearly 5% in the intraday period. As of press release, it rose 3.66% to HK$1.7, with a turnover of HK$4.6441 million.
Tianjin Development Holdings Expects Up to 80% Jump in 2023 Profit
Tianjin Development Holdings (HKG:0882) expects a 70% to 80% year-over-year jump in its net profit in 2023 from HK$358.1 million in the previous year, according to a Wednesday Hong Kong Stock Exchange
Tianjin Development (00882.HK) Yingxi: Net profit is expected to increase by about 70% to 80% year-on-year in 2023
Gelonghui, March 13, 丨 Tianjin Development (00882.HK) announced that the Group expects to record comprehensive net profit attributable to company owners for the year ended December 31, 2023, which may increase by about 70% to 80% from the comprehensive net profit attributable to company owners of HK$358 million for the year ended December 31, 2022. This increase in expectations is mainly due to (i) Lisheng Pharmaceutical Co., Ltd. recorded a one-time revenue of approximately HK$265 million during the year on the acquisition and storage of industrial land and housing at 491 Huanghe Road, Nankai District, Tianjin; (ii) due for the year ended 31 December 2023
Analysis
Price Target
No Data
